Alluvi, previously BI 4744, presents a notable advance in weight control care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates remarkable efficacy in patient trials, potentially surpassing https://alluvi-peptides579282.blogcheer.com/profile